Navigation Links
Labopharm announces details for first quarter results conference call and annual meeting
Date:4/23/2009

LAVAL, QC, April 23 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced the dates and times of its first quarter fiscal 2009 results conference call and Annual Meeting of Shareholders.

First Quarter Results Conference Call

On Thursday, May 7 at 8:30 a.m. (ET) Labopharm will host a conference call to discuss its first quarter 2009 financial results. Labopharm will report its first quarter 2009 financial results via news release at approximately 7:00 a.m. the same day.

To access the conference call by telephone, dial 416-644-3420 or 1-800-732-0232. Please connect approximately 15 minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Thursday, May 14, 2009 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21303738 followed by the number sign.

A live audio webcast of the conference call will be available at www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.

Annual Meeting of Shareholders

Labopharm will hold its Annual Meeting of Shareholders on Thursday, May 7 at 11:00 am ET at the Montreal Museum of Fine Arts, Maxwell-Cummings Auditorium, 1379 Sherbrooke Street West, Montreal, Quebec.

A live webcast of the meeting will be available at www.labopharm.com. Please connect at least 15 minutes prior to the meeting to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above website for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally and its second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www.labopharm.com.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... Richmond, Va. (PRWEB) , ... July 20, 2017 , ... ... Daniel McCarter, MD, has joined JenCare Senior Medical Center as Richmond Chief ... of Virginia School of Medicine, and Associate Chief Medical Officer of Ambulatory Services for ...
(Date:7/20/2017)... ... July 20, 2017 , ... For individuals with extended hospital ... adjustable beds used in such facilities are specially designed to accommodate patients with a ... , An inventor from Rochester, Ind., has invented the patent-pending PORTABLE ARM REST, ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... to the development of non-invasive devices and systems for monitoring cardiopulmonary diseases, announced ... Proceeds will be used to complete regulatory submissions and fund final engineering and ...
(Date:7/20/2017)... ... July 20, 2017 , ... TCGRx announced today ... existing adherence automation lines. The ATP® Mini and InspectRx® Mini are ... standard products, but at a size and price point that can help pharmacies ...
(Date:7/20/2017)... ... 20, 2017 , ... A budget proposal to switch to an alternate consumer ... adjustment (COLA) is a bad deal for older and disabled Americans, says The ... grow even more slowly than the conventional one that is currently used to determine ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... 10, 2017  The tenth annual BioPharm America™ ... at the Sheraton Boston Hotel, September 26–27. ... to global decision makers and innovative biotech startup companies. ... leaders during two impactful days. BioPharm America is now ... additional networking opportunities with 4,500+ life science industry influencers ...
(Date:7/5/2017)... 2017 Wolfmet 3D  printed tungsten collimator manufactured by M&I ... manufacturing combine to progress molecular radiotherapy imaging. In ... unable to accurately quantify the radiation absorbed by those patients ... success of this radiotherapy treatment has been available — that ... ...
(Date:7/5/2017)... 5, 2017   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... ("BioLife"), today announced that it has reached an agreement ... largest shareholder, to modify its existing credit facility effective ... modification, WAVI agreed to exchange its existing $4.25 million ...
Breaking Medicine Technology: